Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer - Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00010179

Locations


Canada, Alberta
	Tom Baker Cancer Center - Calgary
	Calgary, Alberta, Canada, T2N 4N2

Canada, British Columbia
	BCCC - Cancer Center for the Southern Interior
	Kelowna, British Columbia, Canada, V1Y 5L3
	British Columbia Cancer Agency
	Vancouver, British Columbia, Canada, V5Z 4E6

Canada, Manitoba
	CancerCare Manitoba
	Winnipeg, Manitoba, Canada, R3E 0V9

Canada, Nova Scotia
	Nova Scotia Cancer Centre
	Halifax, Nova Scotia, Canada, B3H 1V7

Canada, Ontario
	Queen's University
	Kingston, Ontario, Canada, K7L 3N6

Canada, Quebec
	Royal Victoria Hospital - Montreal
	Montreal, Quebec, Canada, H3A 1A1

Canada, Saskatchewan
	Royal University Hospital
	Saskatoon, Saskatchewan, Canada, S7N 0XO

United Kingdom, England
	Christie Hospital N.H.S. Trust
	Manchester, England, United Kingdom, M20 4BX
	City Hospital NHS Trust
	Birmingham, England, United Kingdom, B18 7QH
	Newcastle General Hospital
	Newcastle Upon Tyne, England, United Kingdom, NE4 6BE
	Royal Marsden NHS Trust
	London, England, United Kingdom, SW3 6JJ
	Weston Park Hospital
	Sheffield, England, United Kingdom, S1O 2SJ

United Kingdom, Scotland
	Beatson Oncology Centre
	Glasgow, Scotland, United Kingdom, G11 6NT

Sponsors and Collaborators

National Cancer Institute of Canada

Investigators


Study Chair:	Robert N. Grimshaw, MD	Nova Scotia Cancer Centre